Introduction
The cells of the prostate gland remain androgen and endocrine sensitive even during malignant transformation. It is now clear that they remain endocrine dependent at quite advanced stages of the disease, thereby allowing for more varied and innovative hormonal therapies even in patients who have relapsed after castration. At each stage of the disease it is increasingly important that urologists assess the patient's hormonal situation in order that subsequent therapies may be tailored to his needs in terms of survival and quality of life and also to be effective at the stage that his prostate cancer has reached.
Hormonal status of patients with prostate cancer
At a recent consensus meeting of the WHO on the future of clinical trials in prostate cancer, a group of urologists, oncologists and basic scientists who were deliberating upon the design of trials for patients with so-called hormone refractory disease, came to the conclusion that the classi®cation of patients with prostate cancer was in its present form inadequate and needed to be modi®ed. The development of hormone refractory disease is not a single step. 1 It is possible that this process may be delayed by the careful use of hormonal therapies which do not reduce testosterone to castrate level, followed by those that do, followed by other endocrine manipulations which may affect the cancer cell even though testosterone levels are in the castrate range. Furthermore, there is some evidence that even in so-called hormone refractory disease there will remain a number of cells in the cancer which are dependent on androgen or other endocrine stimulation and therefore there is an indication that, even with the use of experimental chemotherapy or immunotherapy, there is justi®cation to maintain some form of hormonal suppression. 2 Table 1 summarizes the conclusions of that working party of the WHO conference on the classi®cation of patients with prostate cancer.
deleterious for patients in terms of survival have been shown to be¯awed. 3 At least 60% of patients were given hormonal therapy at an early stage before objective progression of the disease had been proven. The more recent MRC study (coordinator Professor David Kirk, Glasgow), where hormonal therapy by castration, surgical or medical, are offered to patients with all stages of advanced disease, locally advanced or metastatic, has been heavily criticized. The criticisms include the follow-up schedule which only required one Clinical Report Form per year Ð evidence suggests that the majority of patients were seen at 3-monthly intervals, at least during the ®rst 2 y. Twenty-nine patients apparently died from prostate cancer without receiving hormonal therapy. Further analysis suggest this ®gure is probably 15 and at least three of these patients constantly refused therapy and ®ve patients died of anaemia and heart failure Ð not proven to be due solely to metastatic prostate cancer. Nevertheless, there is little doubt that, with well over 50% of the patients dead, early hormonal therapy appeared to offer an advantage in all groups of patients but most particularly in those with non-metastatic disease. Even in patients with metastatic disease early hormonal therapy prevented major complications such as spinal cord compression, pathological fractures, ureteric obstruction and bladder out¯ow obstruction. 4 A recently completed study by the EORTC (study 30891, coordinator professor Urs Studer, Bern) has included 1003 patients and the criticisms levelled at the MRC study concerning the follow-up schedule were addressed by rigorous 3-monthly followup since the study was started in 1990. The therapeutic results of the study are not yet available, but that the study was allowed to proceed until 1000 patients had been recruited while under the watchful eye of a Data Monitoring Committee might suggest that if there is a difference in overall survival it will be comparatively small. Another EORTC study (30846, study coordinator Professor Fritz Schro È der, Rotterdam) of patients with lymph node positive disease at the time of intended radical prostatectomy has also recently been completed. Again, the overall therapeutic results are not yet available. In a group of patients from Rotterdam and Amsterdam in this study there is, however, clear evidence that progression-free survival is improved by the order of 100% in patients who were offered immediate hormonal therapy at the time of diagnosis. In all these studies the greatest bene®t of early hormonal therapy appears to be in those presenting with non-metastatic or small volume metastatic prostate cancer. 5 The conclusion which may be drawn is that hormonal therapy should be offered early to patients in whom there is evidence that cure is no longer possible; it may thus need to be continued for a long period of time. With patients presenting with prostate cancer earlier in the course of the disease, those patients deemed as no longer curable include all those listed in Table 2 .
From studies in Sweden and the US it is clear that untreated some of these patients have a symptom-free survival of at least 5 y. 6 From the other studies cited above, the treated survival may be 8 ± 10 y. The importance of these observations is that if these patients are to be treated early they must clearly be treated with the least toxic hormonal manipulation which has been shown to be effective.
The therapies Castration
Often regarded as the gold standard therapy in advanced prostate cancer, castration has been offered in the past to patients with localized disease and advanced metastatic disease, with differing results. There is no doubt that around 80% of all patients with prostate cancer will react positively to castration in the sense that their cancer will regress. In those with metastatic disease that regression lasts between 18 months and 3 y. 7 In localized disease it may lasts as long as 10 y. Castration is simple to perform and can be carried out under local anaesthetic in patients with co-morbid conditions that might otherwise preclude surgery. The subcapsular operation is the most popular, leaving as it does two small structures in the scrotum which nevertheless give the feel and appearance that the patient still has testicles. In those patients treated with castration for early localized disease in the past, the longterm side-effects are very considerable. In particular the loss of the male body image, the loss of libido, the loss of potency, the loss of muscle mass, feelings of lethargy and inadequacy and the inability to concentrate are very important. More recently, Daniell 8 has shown there is clear evidence that osteoporosis is a serious long-term effect of castration. Around 15% of fractures occuring in patients with advanced prostate cancer occur at sites of osteoporosis caused by castration either surgical or medical, and 85% are pathological fractures through boney metastases. While castration gives the most immediate effect in patients with advanced, painful, disease, its use in patients with early localized disease or PSA recurrence after radical prostatectomy needs to be tempered by the knowledge that these patients will almost certainly live long enough to develop all of the serious side-effects of this procedure.
LHRH-agonists
In supraphysiological doses it appears that synthetic LHRH-agonists, some of which are as much as 100Â more powerful than the natural hormone, can by a process of tachyphylaxis block the production of LH from the pituitary. Often described as the medical equivalent to surgical castration, the same side-effect pro®le exists for this therapy as for surgical removal of the gonads. 9 For the ®rst 2 weeks of therapy, certainly in patients with metastatic disease, it is important that an anti-androgen, steroidal or non-steroidal, or stilbestrol is given to prevent disease¯are from the steep rise in testosterone that occurs in the ®rst 2 weeks of administration of an LHRH-agonist. Recently there has been some questioning of the equivalence of LHRH-agonists to castration. It has been noted for instance that some patients after surgical castration respond to LHRHagonist therapy. Receptors for LHRH or LHRH-like peptides exist on prostate cancer cells and a direct inhibitory effect on prostate cancer cell growth has been shown in explant experiments before there is a reduction in serum testosterone. 10 
LHRH-antagonists
Although still at a relatively early stage of development, these compounds would have the advantage that an antiandrogen would not be necessary to suppress the rising testosterone in the ®rst 2 weeks of therapy. There are still problems in producing a long-term depot preparation of an LHRH-antagonist and histamine release may give rise unwelcome side-effects in a signi®cant number of patients. 11 Androgen receptor antagonist anti-androgen
There are two classes of anti-androgen, steroidal and nonsteroidal. Both classes have the ability to block androgen function at the receptor level. The steroidal anti-androgens have the advantage of blocking LH production in the pituitary because of their progestational properties.
Non-steroidal anti-androgens
At the present time there are three non-steroidal antiandrogens, two of which are recommended for monotherapy and one of which is recommended only as part of combination therapy, the so-called maximum androgen blockade. 12 In a number of studies both¯utamide and bicalutamide have been shown to be equivalent to surgical castration, 13 whereas with nilutamide there has only been one phase II study of 26 patients which showed it to be effective in terms of reducing the pain felt by these patients, who had metastatic disease, and in reducing the serum acid phosphatase level. 14 The various trials of these compounds are summarized in Tables 3 ± 5 .
Steroidal anti-androgen
At the present time only CPA and MPA are available in Europe although chlormadidone is a steroidal anti-androgen which enjoys wide popularity in Japan. In a number of studies CPA and chlormadidone were shown to be as ef®cient as orchiectomy, although MPA has never been demonstrated to be equivalent. 16, 17 The advantages of a steroidal anti-androgen is its two-pronged attack on the prostate cancer. Being steroidal it inhibits the production of LH and therefore lowers testerone levels at the same time as blocking androgen receptors in the prostate cancer itself and metastases. However, being steroidal these antiandrogens have cardiovascular side-effects in 8 ± 15% of patients as well as causing¯uid retention, gastrointestinal side-effects and gynaecomastia in 12%. Signi®cant hepatotoxicity has been seen with CPA in a few patients. Although the cardiovascular side-effects are less frequent than with oestrogens, their severity appears to be quite considerable. 7 
Oestrogens
In the VACURG and early EORTC studies oestrogens were administered orally in relatively high doses, eg 5 and 3 mg daily. In later studies, eg EORTC 30805, DES was given in a dose of 1 mg once a day. In this study, although testosterone levels were not reduced to the castrate range, the clinical ef®cacy appeared to be equivalent to orchiectomy or orchiectomy the administration of a steroidal anti-androgen. There is no doubt from the early VACURG studies and early EORTC studies that oestrogens are as effective as castration in treating advanced prostate cancer. 19 They are slightly more effective in decreasing the number of patients dying of prostate cancer, but their high incidence of cardiovascular effects, between 25% and 36% in different studies, means that the overall survival remains the same. Oestrogens have an unfortunate list of other sideeffects including gynaecomastia, weight gain,¯uid retention, loss of libido, impotence and various gastrointestinal side-effects. Like castration they induce suppression of the immune response and lead to a persistent and sometimes therapy-resistant anaemia. In Scandinavia, 20 oestrogens remain very popular and have been used systemically for many years. Although the injections are painful, the incidence of cardiovascular side-effects is less than with oral oestrogens, and if the administration of depot oestrogens by a parenteral route could be perfected, then a new alternative as primary therapy may emerge.
Experimental work is continuing to develop techniques for administering oestrogen through the skin, either with plasters or with gel preparations. A recent study, SPG 05, has just been completed in Scandinavia, comparing parenteral oestrogens to maximal androgen blockade. The therapeutic results are not yet available, but in the oestrogen arm the cardiovascular side-effects, although not as great as with oral administration, were signi®cant (personal communcation, Iversen).
The recent demonstration of an independent cytotoxic effect of oestrogen on prostate cancer cells has led to its use in patients relapsing after castration or MAB. In one study, 21 PSA and clinical responses were in seen in 43% of 21 patients.
Maximal androgen blockade (MAB)
Following the work of Bracchi, 22 the EORTC 23 and Labrie, 24 in the 1980s and early 1990s, MAB appeared to be the treatment choice for all patients that are presenting with metastatic disease. The ®rst Intergroup study 0036 with 608 patients (study coordinator Dr David Crawford) 25 showed an advantage, particularly in patients with early stage disease, for this therapy when compared to LHRH alone. These results were supported by a large study of castration nilutamide, 26 and the EORTC study 30853. 27 However, a number of other studies, notably the DAPROCA study, showed no advantage for combination therapy against surgical castration, nor did the international study of Zoladex against Zoladex ¯utamide. 28 A second study was carried out by the NCl including 1176 patients, where surgical castration placebo was compared with surgical castration ¯utamide. In all groups, those with small volume and high volume disease, there was no difference between the two treatment arms. 31 The most recent metanalysis of 27 studies of MAB, including over 8000 patients, of whom 6000 have died, has come to the same conclusion that overall there is no advantage for MAB over castration. However, if the studies are subdivided into those using a non-steroidal anti-androgen with castration medical or surgical and those using a steroidal, it seems that there is a marginal advantage for MAB using a non-steroidal anti-androgen over surgical castration. There is no advantage for MAB using a steroidal anti-androgen with an LHRH-agonist; on the contrary, it seems that castration is better than this particular combination. 30 
Minimal androgen blockade
Trachtenberg and others 32 have looked at the use of ®nes-teride, a 5a reductase inhibitor, combined with a low dose non-steroidal anti-androgen in patients with advanced Tailoring of hormonal therapy DWW Newling disease and compared this to castration. There appears to be no difference in ef®cacy between the two therapies. The side-effects of the combination of Proscar a non-steroidal anti-androgen were minimal as opposed to those with castration, which were considerable. In patients with small volume, localized disease, minimal androgen blockade may well be a reasonable start therapy.
The treatment of the hormone naive patient
Patients presenting with symptomatic, metastatic prostate cancer have a poor prognosis, and 90% are dead within 2 y. Although hormonal therapy will have some in¯uence on these patients, it is limited and the most important feature of the treatment is the removal of symptoms. In all studies, MAB has been shown to be most effective for this group of patients. However, in patients with small volume metastatic disease, although in two studies MAB appeared to be of bene®t, in other studies these patients responded well, at least initially, to monotherapy either with a non-steroidal or steroidal anti-androgen. For theoretical reasons the latter would seem to be the most appropriate in these patients. On the other hand, in patients presenting with locally advanced disease and certainly in those with a rising PSA after radical prostatectomy or radiotherapy the prognosis is good and many of these patients will survive 8 ± 10 y. Clearly, the sideeffects of castration or MAB must be avoided in these patients and a simpler therapy may be instituted, such as monotherapy with a non-steroidal anti-androgen. 29 
Treatment after primary hormonal relapse
Many patients who have received initial therapy with a non-steroidal anti-androgen, or even a steroidal antiandrogen, will still have measurable levels of testosterone in the blood. The aim of the second line therapy in these patients will be to convert these levels to castration levels. For those patients who have already reached castrate levels, there will be some advantage to be achieved in blocking the production of androgens from the adrenals, in other words conversion from simple medical or surgical castration to MAB. In patients with far advanced metastatic disease, who have already received MAB, the second line hormonal therapy would be anti-androgen withdrawal in the ®rst instance.
Treatment after secondary and tertiary relapse
Patients who have already received MAB and may or may not have responded to anti-androgen withdrawal, are coming to the limit of their endocrine manipulations.
On the other hand patients who have been converted to castration or MAB still have the opportunity to responsed to other endocrine manipulations.
Those patients who were originally treated for advanced metastatic disease will now be endocrine insensitive. On the other hand patients who have reached the stage of MAB or have recently had an anti-androgen withdrawal, may respond to oestrogens, or a combination of oestrogens and nor nitrogen mustard (estracyt), or prolactin inhibitors such as bromocryptine. There will be in all groups of patients candidates for experimental chemotherapy or immunotherapy, who at this stage, because their general condition remains good, may well achieve a substantial symptomatic response and even prolongation of survival. The therapeutic options for these patients include combinations of estracyt taxanes, VP16 or cyclophosphamide. Mitomycin is a chemotherapeutic agent which has been shown to be effective in prostate cancer that has relapsed after MAB, and may have a role to play here. 1 In this patient group the quantity of their remaining life is rarely an important issue. New therapeutic interventions such as the use of Mitoxantrone or endothelian 1A receptor antagonists, or other new chemotherapeutic manipulations, must be assessed in terms of the quality of our patients' lives as well as prolongation of survival, and in many instances the former will be more important.
Intermittent hormonal therapy
The work of Buchovsky and others has demonstrated an apparent postponement of the development of hormone independence by the use of intermittent MAB. 33 There are no results of phase III studies comparing intermittent to constant hormonal therapy, but comparison of phase II studies with historical controls appears to show no disadvantage for this manoeuvre. Although it would clearly be inappropriate to offer intermittent therapy to patients with symptomatic metastatic disease, it may well have a role to play in patients with small volume metastatic disease who have no symptoms, or in patients who have locally advanced disease. There are at the present time a number of phase III studies ongoing both in the Scandinavian Prostate Cancer Study Group and in the NCl and the EORTC. Because this therapy is being offered to patients who have a predictable survival of at least 5 y, it will be some time before the ®nal results are known.
Tailoring hormonal therapy in prostate cancer
With the probable demonstration that early hormonal therapy conveys a bene®t in early stage advanced or recurrent prostate cancer, more attention needs to be given to the hormonal state of the patient and his cancer and adjusting the hormonal therapy to these variables. Although the concepts of neo-adjuvant and intermittent therapy are appealing, there is evidence that the administration of therapies which reduce testosterone to castrate levels is sometimes associated with prolonged symptoms and testosterone levels may be very slow to return to normal after stopping the therapy. 34 Such prolonged testosterone suppression may affect the response of the cancer to subsequent therapeutic manipulations. A possible algorithm for the treatment of prostate cancer that can no longer be cured appears in Tables 9 ± 11 
Conclusions
The algorithm described above has been developed as a result of a study of the results of clinical trials of all the therapies mentioned in the second section of this article. For urologists to give the best therapy under all circumstances to their patients, they not only need to have a sound knowledge of these trials and their implications but to tailor the results of these trials and their therapeutic ef®cacies to the acceptable side-effects for the patient in the light of his hormonal situation. The EORTC GUGroup will be launching a study of step-up therapy compared to early watchful waiting followed by MAB on progression in the near future. 
